Month: May 2022

Sterile Medical Packaging Market Worth $73.67 Billion at 7.5% CAGR by 2022-2029 | Global Sterile Medical Packaging Industry SWOT Analysis and Growth Outlook

Written by Customer Service on May 16, 2022. Posted in Mergers And Acquisitions.

Companies covered in sterile medical packaging market are Amcor Plc (Switzerland), Placon (U.S.), DuPont (U.S.) , Steripack Ltd. (Ireland), Wipak Group (Finland), Nelipak Healthcare (U.S.), Tekni-Plex (U.S.), Sonoco (U.S.), BillerudKorsnäs AB (Sweden), ProAmpac (U.S.), West Pharmaceutical Services, Inc. (U.S.), Riverside Medical Packaging Company Ltd (U.K.), Oliver Healthcare Packaging (U.S.), GS Medical Packaging (Canada), Orchid (U.S.), Technipaq Inc. (U.S.) and more players profiled.. Pune India, May 16, 2022 (GLOBE NEWSWIRE) — The global sterile medical packaging market size was valued at $39.79 billion in 2021. The market is projected to grow from $44.29 billion in 2022 to $73.67 billion by 2029, exhibiting a CAGR of 7.5% during the forecast period. This information is published by Fortune Business Insights, in its report,...

Proactive news headlines including RPM Automotive Group, Galena Mining, Allup Silica and Evolution Energy Minerals

Written by Customer Service on May 16, 2022. Posted in Mergers And Acquisitions.

Sydney, May 16, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:RPM Automotive Group Ltd (ASX:RPM) has completed the acquisition of Victoria Wide Tyre Service with that business now trading as a subsidiary and adding to RPM’s strong position in the Australian automotive aftermarket. Click here Galena Mining Ltd (ASX:G1A) has hit the 63% completion milestone at its Abra Base Metals Mine in WA’s Gascoyne region. Click here Allup Silica Ltd (ASX:APS)’s independent metallurgical test-work has demonstrated the potential to produce high-quality silica sand from the Sparkler Silica Exploration Project in Western Australia. Click here Evolution Energy Minerals Ltd (ASX:EV1) has appointed highly experienced, leading financial...

Notes of the Board of Directors on Q1 2022

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

NOTES OF THE BOARD OF DIRECTORS ON Q1 2022 REGULATED INFORMATIONBrussels, 16 May 2022 07.30 am CEST KEY FIGURESFor Q1 2022 we note the following key data:Net result of €21.8 million, or €2.18 per share Rental income up by €2.1 million Loan-to-value on the investment portfolio down by two percentage points at 53.7% Sale of the buildings The Crescent (Anderlecht, Belgium) and Monnet 4 (Kirchberg, Luxembourg) resulting a profit of €5 million The average financing cost fell from 2.07% in 2021 to 2.05% on 31 March 2022 Developments on Cloche d’Or continue apace, with the sale of the Kockelscheuer building in January 2022 and delivery of the Darwin II building At the Tour&Taxis site the apartments of the first-phase of Park Lane are gradually being delivered, while events can once again take place in the Sheds, Maison de la Poste and...

RENAULT GROUP: Renault Group signs agreements to sell Renault Russia and its controlling interest in AVTOVAZ

Written by Customer Service on May 16, 2022. Posted in Mergers And Acquisitions.

PRESS RELEASE May 16, 2022Renault Group signs agreements to sell Renault Russia and its controlling interest in AVTOVAZ Boulogne-Billancourt, May 16th, 2022 – The Board of Directors of Renault Group unanimously approved the signing of agreements to sell 100% of Renault Group’s shares in Renault Russia to Moscow City entity and its 67.69% interest in AVTOVAZ to NAMI (the Central Research and Development Automobile and Engine Institute). The closing of these transactions is not subject to any conditions, and all required approvals have been obtained. The agreement provides for an option for Renault Group to buy back its interest in AVTOVAZ, exercisable at certain times during the next 6 years. “Today, we have taken a difficult but necessary decision; and we are making a responsible choice towards our 45,000 employees...

Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement

Written by Customer Service on May 16, 2022. Posted in Public Companies.

Saint-Herblain (France), May 16, 2022 – Valneva SE, a specialty vaccine company, today announced that it has received a notice from the European Commission (“EC”) of intent to terminate the advance purchase agreement (“APA”) for Valneva’s inactivated whole-virus COVID-19 vaccine candidate VLA2001. The APA provides the EC with a right to terminate the APA if VLA2001 had not received a marketing authorization from the European Medicines Agency (“EMA”) by April 30, 2022. Based on the terms of the APA, Valneva has 30 days from May 13, 2022 to obtain a marketing authorization or propose an acceptable remediation plan. The Company will work with the EC and the participating EC member states to agree to a remediation plan and to make VLA2001 available to those member states who still wish to receive it. Thomas Lingelbach, Chief Executive Officer...

Arrangement of NoHo Partners’ convertible loan granted by Tesi – investors include company management and domestic investors

Written by Customer Service on May 16, 2022. Posted in Public Companies.

NoHo Partners Plc INVESTOR NEWS 16 May 2022 at 7:00 Arrangement of NoHo Partners’ convertible loan granted by Tesi – investors include company management and domestic investorsThe management and domestic investors of NoHo Partners Plc have acquired the majority of the convertible capital loan granted to the company by Finnish Industry Investment Ltd (Tesi) and converted their purchase into new shares in the company. The company repaid the remaining portion of the loan principal and interest, approximately one sixth, to Tesi using its cash assets. As the result of the arrangement, the company’s equity is strengthened and its net debt decreases by over MEUR 10. The arrangement allows the company financial flexibility, which will drive the implementation of future growth projects as part of the company’s strategy for profitable growth. The...

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Written by Customer Service on May 16, 2022. Posted in Public Companies.

— The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF — Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF patients UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced U.S. Food and Drug Administration’s (FDA) acceptance of an Investigational New Drug (IND) application supporting the clinical development of ANG-3070 in idiopathic pulmonary fibrosis (IPF) and clearance to begin a Phase 1b study of ANG-3070 in patients with IPF. ANG-3070 is an oral tyrosine kinase inhibitor targeting platelet-derived growth factor receptor alpha and...

Pinduoduo to Report First Quarter 2022 Unaudited Financial Results on May 27, 2022

Written by Customer Service on May 16, 2022. Posted in Public Companies.

SHANGHAI, China, May 16, 2022 (GLOBE NEWSWIRE) — Pinduoduo Inc. (“Pinduoduo”) (NASDAQ: PDD) today announced that it will report its unaudited financial results for the first quarter ended March 31, 2022, before U.S. markets open on Friday, May 27, 2022. Pinduoduo’s management will hold an earnings conference call at 7:30 AM U.S. Eastern Time on May 27, 2022. (7:30 PM Beijing/Hong Kong Time on the same day). The conference call will be webcast live at https://investor.pinduoduo.com/investor-events. The webcast will be available for replay at the same website following the conclusion of the call. About Pinduoduo Inc. Pinduoduo connects millions of agricultural producers with consumers across China. Pinduoduo aims to bring more businesses and people into the digital economy so that local communities can benefit from the increased...

KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

Written by Customer Service on May 16, 2022. Posted in Mergers And Acquisitions.

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration (FDA) as early as the First Quarter of 2023 Conference call and live audio webcast with slide presentation is scheduled for tomorrow, May 16, 2022, at 8:30 a.m., EDT CELEBRATION, Fla., May 15, 2022 (GLOBE NEWSWIRE) — KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced a definitive agreement with Orphazyme A/S (in reconstruction) (ORPHA.CO; ORPH) (Orphazyme)...

Euro Manganese Reports Second Quarter 2022 Financial Results and Project Developments

Written by Customer Service on May 15, 2022. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, May 15, 2022 (GLOBE NEWSWIRE) — Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the “Company” or “EMN“) is pleased to announce key developments during the second quarter 2022 and to date. The Company has now filed its second quarter Financial Statements and Management’s Discussion and Analysis (“MD&A”). Key DevelopmentsFirst shipment of the demonstration plant underway. The first consignment was shipped on April 30, 2022 and the final consignment is expected to be shipped in the coming weeks. Both shipments are being made by ocean freight from China, a change from rail, due to the Russia-Ukraine conflict. Delivery of the initial shipment is expected on site in June. Assembly of the demonstration plant modules will commence upon delivery. Completion...

Month: May 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals